Limits...
Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?

Zheng W, Qiu S, Huang L, Pan J - Pak J Med Sci (2015 Jul-Aug)

Bottom Line: GP regimen (gemcitabine + cisplatin) was an independent prognostic factor for OS (P = 0.038) and it had a trend toward improved DMFS (P = 0.109).TP regimen (taxol + cisplatin) was only a significant prognostic factor for DMFS (P =0.038).GP regimen may be superior to TP/FP regimen (fluorouracil + cisplatin) in treating locoregionally advanced NPC.

View Article: PubMed Central - PubMed

Affiliation: Wei Zheng, Department of Radiation Oncology, Cancer Hospital of Fujian Medical University, Fuzhou, Fujian, China. Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China. Teaching Hospital of Fujian Health College, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.

ABSTRACT

Objective: To investigate the outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) treated with induction chemotherapy followed by chemoradiotherapy.

Methods: Between June 2005 and October 2007, 604 patients with locoregionally advanced NPC were analyzed, of whom 399 and 205 were treated with conventional radiotherapy and intensity-modulated radiotherapy (IMRT) respectively. Meanwhile, 153 patients received concurrent chemotherapy, and 520 were given induction chemotherapy.

Results: With a median follow-up time of 65 months, the 3-, and 5-year overall survival (OS), locoregional free survival (LRFS), and distant-metastasis free survival (DMFS) rates were 82.5% vs. 72.6%, 90.6% vs. 87.1%, and 82.5% vs. 81.2%, respectively. Induction chemotherapy was not an independent prognostic factor for OS (P=0.193) or LRFS, but there was a positive tendency for DMFS (P=0.088). GP regimen (gemcitabine + cisplatin) was an independent prognostic factor for OS (P = 0.038) and it had a trend toward improved DMFS (P = 0.109). TP regimen (taxol + cisplatin) was only a significant prognostic factor for DMFS (P =0.038).

Conclusions: Adding induction chemotherapy had no survival benefit, but GP regimen benefited overall survival and had a trend toward improved DMFS. GP regimen may be superior to TP/FP regimen (fluorouracil + cisplatin) in treating locoregionally advanced NPC.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier curves of overall survival by TP, GP and FP regimens.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4590383&req=5

Figure 1: Kaplan-Meier curves of overall survival by TP, GP and FP regimens.

Mentions: The associations between induction chemotherapy and OS/LRFS/DMFS rates are presented in Table-II. Induction chemotherapy regimens did not fit for LRFS log-rank test. Fig.1 and Fig.2 illustrate the association between OS and DMFS with different induction regimens (TP regimen; GP regimen; FP regimen).


Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?

Zheng W, Qiu S, Huang L, Pan J - Pak J Med Sci (2015 Jul-Aug)

Kaplan-Meier curves of overall survival by TP, GP and FP regimens.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4590383&req=5

Figure 1: Kaplan-Meier curves of overall survival by TP, GP and FP regimens.
Mentions: The associations between induction chemotherapy and OS/LRFS/DMFS rates are presented in Table-II. Induction chemotherapy regimens did not fit for LRFS log-rank test. Fig.1 and Fig.2 illustrate the association between OS and DMFS with different induction regimens (TP regimen; GP regimen; FP regimen).

Bottom Line: GP regimen (gemcitabine + cisplatin) was an independent prognostic factor for OS (P = 0.038) and it had a trend toward improved DMFS (P = 0.109).TP regimen (taxol + cisplatin) was only a significant prognostic factor for DMFS (P =0.038).GP regimen may be superior to TP/FP regimen (fluorouracil + cisplatin) in treating locoregionally advanced NPC.

View Article: PubMed Central - PubMed

Affiliation: Wei Zheng, Department of Radiation Oncology, Cancer Hospital of Fujian Medical University, Fuzhou, Fujian, China. Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China. Teaching Hospital of Fujian Health College, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.

ABSTRACT

Objective: To investigate the outcome of locoregionally advanced nasopharyngeal carcinoma (NPC) treated with induction chemotherapy followed by chemoradiotherapy.

Methods: Between June 2005 and October 2007, 604 patients with locoregionally advanced NPC were analyzed, of whom 399 and 205 were treated with conventional radiotherapy and intensity-modulated radiotherapy (IMRT) respectively. Meanwhile, 153 patients received concurrent chemotherapy, and 520 were given induction chemotherapy.

Results: With a median follow-up time of 65 months, the 3-, and 5-year overall survival (OS), locoregional free survival (LRFS), and distant-metastasis free survival (DMFS) rates were 82.5% vs. 72.6%, 90.6% vs. 87.1%, and 82.5% vs. 81.2%, respectively. Induction chemotherapy was not an independent prognostic factor for OS (P=0.193) or LRFS, but there was a positive tendency for DMFS (P=0.088). GP regimen (gemcitabine + cisplatin) was an independent prognostic factor for OS (P = 0.038) and it had a trend toward improved DMFS (P = 0.109). TP regimen (taxol + cisplatin) was only a significant prognostic factor for DMFS (P =0.038).

Conclusions: Adding induction chemotherapy had no survival benefit, but GP regimen benefited overall survival and had a trend toward improved DMFS. GP regimen may be superior to TP/FP regimen (fluorouracil + cisplatin) in treating locoregionally advanced NPC.

No MeSH data available.


Related in: MedlinePlus